Camtek Ltd. (NASDAQ:CAMT)’s share price rose 2.9% during mid-day trading on Wednesday . The stock traded as high as $2.81 and last traded at $2.80, with a volume of 83,475 shares changing hands. The stock had previously closed at $2.72.

CAMT has been the topic of several recent analyst reports. Zacks Investment Research upgraded Camtek from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Needham & Company LLC lifted their price target on Camtek from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Friday, July 22nd. TheStreet upgraded Camtek from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Finally, B. Riley reiterated a “buy” rating and issued a $3.25 price target on shares of Camtek in a research note on Monday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $3.56.

The stock’s market cap is $95.44 million. The firm has a 50 day moving average price of $2.25 and a 200 day moving average price of $2.03.

Camtek (NASDAQ:CAMT) last released its quarterly earnings results on Thursday, July 21st. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The company had revenue of $27.30 million for the quarter, compared to analyst estimates of $26.05 million. Equities research analysts forecast that Camtek Ltd. will post $0.15 earnings per share for the current fiscal year.

Camtek Ltd. (Camtek) designs, develops, manufactures and markets automated solutions for production processes and for the semiconductor fabrication and printed circuit boards industries. The Company offers products-based on two core technologies: AOI and functional ink technology (FIT). The Company’s AOI systems are computerized systems that optically inspect various types of electronic product components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.